Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Immunotherapy
  • Receptor, Epidermal Growth Factor

abstract

  • Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Further studies of cetuximab will evaluate the use of cetuximab in conjunction with first-line and adjuvant treatments for this disease.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.10.182

PubMed ID

  • 14993230

Additional Document Info

start page

  • 1201

end page

  • 8

volume

  • 22

number

  • 7